Influence of Lisdexamfetamine Dimesylate on Early Ejaculation—Results from a Double-Blind Randomized Clinical Trial

Abstract

Background: Among male sexual dysfunctions, erectile dysfunction and early ejaculation have the highest prevalence rates. Here, we tested the influence of lisdexamfetamine dimesylate (Vyas®) on early ejaculation. To this end, we performed a double-blind randomized clinical trial among males with early ejaculation. Methods: A total of 46 males with early ejaculation (mean age: 35.23 years) and in stable marital relationships with regular weekly penile–vaginal intercourse were randomly assigned either to the lisdexamfetamine dimesylate condition (30 mg) or to the placebo condition. Compounds were taken about six hours before intended penile–vaginal intercourse. At baseline and four weeks later at the end of the study, participants completed a series of self-rating questionnaires covering early ejaculation. Female partners also rated participants’ early ejaculation profile. Results: Compared to the placebo condition, dimensions of early ejaculation improved over time in the lisdexamfetamine condition, though improvements were also observed in the placebo condition. Conclusions: Among male adults in stable marital relationships with regular weekly penile–vaginal intercourse, lisdexamfetamine dimesylate improved dimensions of early ejaculation. Given that improvements were also observed in the placebo condition, psychological factors such as increased attention to early ejaculation and favorable expectations of the compound should be considered.

Prevalence of Ejaculatory Disorders among Post COVID-19 Egyptian Males

“…In a different study, 251 participants completed the IIEF-5 scale. The IIEF-5's median value dropped from 21 [range 1-25, IQR [14][15][16][17][18][19][20][21][22][23] to 20 [range 1-25, , and the mean score [18.13 ± 6.74 vs. 17.00 ± 7.15, t = 4.867, P < 0.001] differed significantly. Following the epidemic, 31.9% of those surveyed had lower IIEF-5 scores; additionally, they exhibited higher GAD-7 [P =.001], higher PHQ-9 [P = 0.002], a greater percentage of lowered sexual life frequency [P < 0.001], lower sexual life frequency [P = 0.025], and lower frequency of physical activity [P =.007] [17] .…”

“…Despite being one of the most prevalent male sexual illnesses, EJD is still commonly unvalued or ignored due to a number of patient and clinician hurdles. The broad range of EJD involves retrograde ejaculation and painful ejaculation, and it extends from PE via DE to a total incapacity to ejaculate, also referred to as anejaculation [15] . Individuals with these illnesses have a reduced frequency of organic comorbidities like diabetes, hypertension, or dyslipidemia and a higher likelihood of anxiety or depression [16] .…”

Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

“…LDX, a prodrug of Dextroamphetamine, is utilized in the treatment of ADHD in both children and adults [ 30 ]. In Iran, it is marketed under the brand name Vyas [ 31 ]. Alongside stimulant medicines, non-stimulant medications serve as alternative treatment options for ADHD patients [ 32 ].…”